Literature DB >> 21652233

Triple-negative breast cancer: are the imaging findings different between responders and nonresponders to neoadjuvant chemotherapy?

Hiroko Kawashima1, Masafumi Inokuchi, Hiroyuki Furukawa, Seiko Kitamura.   

Abstract

RATIONALE AND
OBJECTIVES: The purpose of the present study was to evaluate the imaging findings of triple-negative breast cancer patients receiving neoadjuvant chemotherapy (NAC) and to investigate whether the findings are different between responders and nonresponders, enabling us to predict the final patient response.
MATERIALS AND METHODS: The subjects included 22 women ages 35-73 years (mean, 50.4 years) with 23 triple-negative breast cancers who underwent NAC. In all cases, a mammography, ultrasound, and magnetic resonance imaging (MRI) were performed a total of three times: before NAC, after the first half of NAC, and after NAC. The mass shape, mass margin, presence of clear intratumoral necrosis, and presence of intratumoral calcification were analyzed. The presence of clear intratumoral necrosis was evaluated on the MRI. If there was a very high signal intensity (similar to that of water) in the tumor on the fat-suppressed T2-weighted MRI scans, we judged it to be clear intratumoral necrosis.
RESULTS: An irregularly shaped mass (P = .018) and the presence of clear intratumoral necrosis (P = .044) were significantly associated with NAC nonresponse in triple-negative breast cancer patients. The mass margin and the presence of intratumoral calcification were not related to the effects after NAC.
CONCLUSIONS: In cases of triple-negative breast cancer involving clear intratumoral necrosis with an irregular mass shape, it is predicted that the effects of neoadjuvant chemotherapy will likely be poor, and therefore, the presence of such image findings may be useful for determining the optimal application of neoadjuvant chemotherapy.
Copyright © 2011 AUR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21652233     DOI: 10.1016/j.acra.2011.04.002

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  6 in total

1.  Development and validation of a nomogram based on pretreatment dynamic contrast-enhanced MRI for the prediction of pathologic response after neoadjuvant chemotherapy for triple-negative breast cancer.

Authors:  Yanbo Li; Yongzi Chen; Rui Zhao; Yu Ji; Junnan Li; Ying Zhang; Hong Lu
Journal:  Eur Radiol       Date:  2021-11-12       Impact factor: 7.034

Review 2.  Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC).

Authors:  Abeer H Abdelhafez; Benjamin C Musall; Wei T Yang; Gaiane M Rauch; Beatriz E Adrada; KennethR Hess; Jong Bum Son; Ken-Pin Hwang; Rosalind P Candelaria; Lumarie Santiago; Gary J Whitman; Huong T Le-Petross; Tanya W Moseley; Elsa Arribas; Deanna L Lane; Marion E Scoggins; Jessica W T Leung; Hagar S Mahmoud; Jason B White; Elizabeth E Ravenberg; Jennifer K Litton; Vicente Valero; Peng Wei; Alastair M Thompson; Stacy L Moulder; Mark D Pagel; Jingfei Ma
Journal:  Breast Cancer Res Treat       Date:  2020-09-13       Impact factor: 4.872

Review 3.  Molecular subtypes and imaging phenotypes of breast cancer.

Authors:  Nariya Cho
Journal:  Ultrasonography       Date:  2016-07-21

4.  Imaging Surveillance for Survivors of Breast Cancer: Correlation between Cancer Characteristics and Method of Detection.

Authors:  A Jung Chu; Jung Min Chang; Nariya Cho; Woo Kyung Moon
Journal:  J Breast Cancer       Date:  2017-06-26       Impact factor: 3.588

Review 5.  Clinical application of magnetic resonance imaging in management of breast cancer patients receiving neoadjuvant chemotherapy.

Authors:  Jeon-Hor Chen; Min-Ying Su
Journal:  Biomed Res Int       Date:  2013-06-05       Impact factor: 3.411

6.  Magnetic resonance imaging features of breast cancer according to intrinsic subtypes: correlations with neoadjuvant chemotherapy effects.

Authors:  Hiroko Kawashima; Masafumi Inokuchi; Hiroyuki Furukawa; Hiroko Ikeda; Seiko Kitamura
Journal:  Springerplus       Date:  2014-05-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.